Medpace Holdings, Inc. MEDP
618.88
(1.71)
(0.28%)
as of 25 Sep
- Market cap
- $17.3B
- P/E
- 35.6×
Follow MEDP
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
35.07 | 35.87 | 29.57 | 30.45 |
P/S ratio |
6.13 | 6.40 | 5.10 | 5.36 | |
P/FCF ratio |
21.38 | 23.76 | 19.21 | 21.11 | |
P/Operating CF |
58.76 | 84.10 | 89.99 | 92.10 | |
P/B ratio |
49.27 | 35.29 | 22.83 | 34.39 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
6.08 | 6.27 | 4.92 | 5.24 | |
EV/EBITDA |
26.78 | 28.18 | 22.28 | 23.86 | |
EV/Operating CF |
20.17 | 22.25 | 17.82 | 19.37 | |
EV/FCF |
21.19 | 23.27 | 18.52 | 20.63 | |
Quick Ratio |
0.51 | 0.67 | 0.78 | 0.66 | |
Current Ratio |
0.57 | 0.74 | 0.85 | 0.73 | |
Net Debt/EBITDA |
(1.92) | (3.10) | (4.40) | (3.27) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
1.23 | 1.24 | 1.33 | 1.53 | |
Operating CF/Net income |
2.22 | 1.43 | 1.23 | 1.33 | |
Capex/Depreciation |
(1.52) | (0.64) | (0.99) | (3.56) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
7.29% | 6.34% | 6.78% | 6.80% | |
Intangible Assets out of Total Assets |
0.40 | 0.35 | 0.33 | 0.34 | |
Share Based Compensation of Revenue |
0.96% | 0.79% | 0.70% | 0.61% | |
Graham Net Nets |
(0.05) | (0.03) | (0.03) | (0.04) | |
Graham Number |
58.67 | 74.88 | 87.67 | 77.62 | |
Earnings Yield |
2.85% | 2.79% | 3.38% | 3.28% | |
Free Cash Flow Yield |
4.68% | 4.21% | 5.21% | 4.74% | |
Revenue per Share |
23.45 | 24.56 | 24.84 | 25.11 | |
Operating CF per Share |
8.75 | 6.68 | 5.34 | 5.75 | |
Capex per Share |
(0.38) | (0.16) | (0.24) | (0.85) | |
Free Cash Flow per Share |
8.37 | 6.52 | 5.10 | 4.90 | |
Cash per Share |
10.14 | 17.23 | 22.95 | 17.84 | |
Shareholders Equity per Share |
10.44 | 15.91 | 21.03 | 15.40 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
10.44 | 15.91 | 21.03 | 15.40 | |
Free Cash Flow |
235.50 | 188.12 | 144.97 | 138.10 | |
Working Capital |
(546.63) | (354.12) | (205.96) | (385.14) | |
Capital Expenditures |
(10.71) | (4.54) | (6.81) | (23.91) | |
Net Current Asset Value |
(722.09) | (526.78) | (392.24) | (573.03) | |
EV/EBIT |
28.29 | 29.66 | 23.39 | 24.99 | |
Capex to Sales |
0.02 | 0.01 | 0.01 | 0.03 | |
Net Profit Margin |
16.84% | 19.07% | 17.53% | 17.16% | |
Price to Operating Income |
28.53 | 30.29 | 24.26 | 25.58 | |
| Other line items | |||||
Average Receivables |
342.25 | 349.26 | 346.40 | 409.86 | |
Average Payables |
26.36 | 30.34 | 47.87 | 40.40 | |
Average Assets |
1,918.54 | 2,038.17 | 2,013.49 | 1,814.43 | |
Average Common Equity |
587.54 | 642.31 | 595.96 | 303.11 |
Columns are period end dates